Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cue Biopharma ( (CUE) ) just unveiled an announcement.
On September 26, 2025, Cue Biopharma announced the appointment of Usman Azam as the new President and CEO, effective September 29, 2025, succeeding Daniel R. Passeri who will retire but remain as a strategic advisor. Dr. Azam’s extensive experience in leading biopharmaceutical companies is expected to enhance Cue Biopharma’s strategic direction and operational capabilities, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (CUE) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including persistent losses and negative cash flows. While the technical analysis provides some neutral signals, the valuation remains weak due to a negative P/E ratio. The recent corporate event offers a slight positive, potentially improving financial flexibility.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of novel cancer drugs and therapies. The company is involved in discovering and advancing innovative treatments for cancer with a market focus on clinical-stage biopharmaceutical advancements.
Average Trading Volume: 263,739
Technical Sentiment Signal: Sell
Current Market Cap: $54.55M
For an in-depth examination of CUE stock, go to TipRanks’ Overview page.